Dr. Furie: #RNL2023 Anifrolumab - anti type 1 IFN receptor- blocks all 5 IFN, 90% IFN gene signature decrease Improved from prior older failed medication sifalimumab which only blocked IFNalpha- only 25% interferon gene signature @RheumNow https://t.co/30oFRwwuTG